Kai M Eggers1, Tomas Jernberg2, Bertil Lindahl3. 1. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. Electronic address: kai.eggers@ucr.uu.se. 2. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. 3. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND: Cardiac troponin (cTn) elevation is a common finding in acutely admitted patients, even in the absence of acute coronary syndrome. In some of these patients, no etiology of cTn elevation can be identified. The term troponinemia is sometimes used to describe this scenario. OBJECTIVES: This study aimed to investigate the associations of cTn levels with clinical findings and long-term outcome in acutely admitted patients with suspected acute coronary syndrome who had been discharged without a specified diagnosis. METHODS: Retrospective registry-based cohort study investigating 48,872 patients (SWEDEHEART [Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies] registry). Patients were stratified into cohorts with cTn levels less than or equal to the assay-specific 99th percentile and separated by assay-specific cTn tertiles in case of higher levels. RESULTS: A cTn level >99th percentile was noted in 9,800 (20.1%) patients. The prevalence of cardiovascular risk factors as well as cardiovascular and noncardiovascular comorbidities increased across higher cTn strata. In total, 7,529 (15.4%) patients had a major adverse event (MAE), defined as the composite of all-cause mortality, myocardial infarction, readmission for heart failure, or stroke (median follow-up 4.9 years). MAE risk was associated with higher cTn strata (hazard ratio for highest assay-specific cTn tertile: 2.59; 95% confidence interval: 2.39 to 2.80; hazard ratio in patients without cardiovascular comorbidities, renal dysfunction, left ventricular dysfunction, or significant coronary stenosis: 3.57; 95% confidence interval: 2.30 to 5.54). CONCLUSIONS: cTn elevation is associated with cardiovascular and noncardiovascular comorbidities and predicts major adverse events in acutely admitted patients, in whom no definite diagnosis could have been established. The term troponinemia is trivializing and should be avoided. Instead, careful work-up is required in these patients.
BACKGROUND: Cardiac troponin (cTn) elevation is a common finding in acutely admitted patients, even in the absence of acute coronary syndrome. In some of these patients, no etiology of cTn elevation can be identified. The term troponinemia is sometimes used to describe this scenario. OBJECTIVES: This study aimed to investigate the associations of cTn levels with clinical findings and long-term outcome in acutely admitted patients with suspected acute coronary syndrome who had been discharged without a specified diagnosis. METHODS: Retrospective registry-based cohort study investigating 48,872 patients (SWEDEHEART [Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies] registry). Patients were stratified into cohorts with cTn levels less than or equal to the assay-specific 99th percentile and separated by assay-specific cTn tertiles in case of higher levels. RESULTS: A cTn level >99th percentile was noted in 9,800 (20.1%) patients. The prevalence of cardiovascular risk factors as well as cardiovascular and noncardiovascular comorbidities increased across higher cTn strata. In total, 7,529 (15.4%) patients had a major adverse event (MAE), defined as the composite of all-cause mortality, myocardial infarction, readmission for heart failure, or stroke (median follow-up 4.9 years). MAE risk was associated with higher cTn strata (hazard ratio for highest assay-specific cTn tertile: 2.59; 95% confidence interval: 2.39 to 2.80; hazard ratio in patients without cardiovascular comorbidities, renal dysfunction, left ventricular dysfunction, or significant coronary stenosis: 3.57; 95% confidence interval: 2.30 to 5.54). CONCLUSIONS:cTn elevation is associated with cardiovascular and noncardiovascular comorbidities and predicts major adverse events in acutely admitted patients, in whom no definite diagnosis could have been established. The term troponinemia is trivializing and should be avoided. Instead, careful work-up is required in these patients.
Authors: Avinainder Singh; Ankur Gupta; Ersilia M DeFilippis; Arman Qamar; David W Biery; Zaid Almarzooq; Bradley Collins; Amber Fatima; Candace Jackson; Patrycja Galazka; Mattheus Ramsis; Daniel C Pipilas; Sanjay Divakaran; Mary Cawley; Jon Hainer; Josh Klein; Petr Jarolim; Khurram Nasir; James L Januzzi; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein Journal: J Am Coll Cardiol Date: 2020-03-10 Impact factor: 24.094
Authors: Michael A Garcia; Justin M Rucci; Khanh K Thai; Yun Lu; Patricia Kipnis; Alan S Go; Manisha Desai; Nicholas A Bosch; Adriana Martinez; Heather Clancy; Ycar Devis; Laura C Myers; Vincent X Liu; Allan J Walkey Journal: Am J Respir Crit Care Med Date: 2021-09-01 Impact factor: 30.528
Authors: Vedant Gupta; Marc Paranzino; Talal Alnabelsi; Karam Ayoub; Joshua Eason; Andin Mullis; John R Kotter; Andrew Parks; Levi May; Sethabhisha Nerusu; Chen Dai; Daniel Cleland; Steve Wah Leung; Vincent Leigh Sorrell Journal: PLoS One Date: 2021-02-09 Impact factor: 3.240
Authors: Anthony Ming-Yu Chuang; Mau T Nguyen; Ehsan Khan; Dylan Jones; Matthew Horsfall; Sam Lehman; Nathaniel R Smilowitz; Kristina Lambrakis; Martin Than; Julian Vaile; Ajay Sinhal; John K French; Derek P Chew Journal: PLoS One Date: 2021-03-12 Impact factor: 3.240
Authors: Valentina Bracun; Joseph Pierre Aboumsallem; Peter van der Meer; Rudolf A de Boer Journal: Curr Oncol Rep Date: 2020-06-09 Impact factor: 5.075